$QSI

Quantum-Si (QSI) aims to lead the 'post-genomic era' with its Proteus protein sequencing platform, which detected 19 amino acids by October 2026. The company delayed Proteus' commercial launch to Q2 2027 but reported positive test results. QSI shares rose 26.36% year-to-date to $1.39, despite a 33.17% drop over the past year. The company posted a net loss of $101.34m in 2025 and expects $1m revenue in 2026. Analysts see potential upside, with a $4.00 price target.

Quantum-Si Inc (QSI) filed an SEC Form 8-K — Other Events. Quantum-Si Regains Compliance with Nasdaq Minimum Bid Price Requirement BRANFORD, Conn., Oct. 15, 2026 (GLOBE NEWSWIRE) — Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI,” or the “Company”), a proteomics company redefining protein analysis through single-molecule protei

Quantum-Si (QSI) announced it has met Nasdaq's minimum bid price requirement, with its share price staying above $1 for 10 consecutive days. The company's shares fell 1.42% on the news. Quantum-Si previously reported a GAAP EPS of -$0.11 and revenue of $0.34M, both beating estimates.

Neuralink, a private brain-computer interface (BCI) company, successfully helped a patient with ALS communicate. Investors cannot buy Neuralink, but two public companies, Quantum-Si (QSI) and Butterfly Network (BFLY), are connected to the BCI field. QSI makes research tools and saw a 7x volume spike, while BFLY supplies ultrasound chips to BCI developers like Merge Labs and Bridge Neurotech.

Quantum-Si (QSI) shares rose 27.87% after announcing its Proteus protein sequencer can now identify 19 of 20 amino acids. CEO Jeff Hawkins called this an important step toward detecting all 20 by year-end 2026. The company aims for a commercial launch in Q2 2027. Founder JM Rothberg, who owns shares, praised the progress on social media.

Quantum-Si Inc (QSI) filed an SEC Form 8-K — Regulation FD Disclosure. Quantum-Si Demonstrates Detection of 19 Amino Acids in Proteus™ Development Program Company is working to deploy 19-amino-acid detection into a developmental sequencing kit and remains confident in demonstrating detection of all 20 amino acids by year-end 2026 BRANFORD, Conn. — O

Quantum-Si Inc (QSI) filed an SEC Form 8-K — Regulation FD Disclosure. 1 ProteusTM The Future of Single-molecule Protein Sequencing World HUPO 2026 Exhibit 99.1 2 Disclaimer and Other Information Forward-looking Statements This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States

Quantum-Si (QSI) reported interim data comparing its Proteus platform with Platinum Pro, showing significant performance improvements in sequencing metrics. Proteus outperformed Platinum Pro in scale, accuracy, and protein identification. The data was presented at the 2026 World HUPO Congress. Quantum-Si expects further improvements before Proteus' launch in Q2 2027.

Quantum-Si (NASDAQ:QSI) reported Q2 2026 revenue of $344,000, down from $591,000 a year earlier, and a Q2 net loss of $23.5 million. The company said Proteus launch timing is revised to early 2027, with initial detection of 19 or 20 amino acids. It expects about $12 million annual operating-expense savings and full-year 2026 revenue near $1 million.

Quantum-Si Incorporated (QSI) reported Q2 adjusted EPS loss of $0.11, better than the Zacks Consensus loss of $0.13. Revenue was $0.34 million, up 4.24% versus the estimate, down from $0.59 million a year earlier. The article cites a Zacks Rank #3 (Hold) and notes upcoming consensus for the next quarter EPS of -$0.13 on $0.27 million revenue.